Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.

More search options...

Schnell, O; Battelino, T; Bergenstal, R; Blüher, M; Böhm, M; Brosius, F; Carr, RD; Ceriello, A; Forst, T; Giorgino, F; et al. Schnell, O; Battelino, T; Bergenstal, R; Blüher, M; Böhm, M; Brosius, F; Carr, RD; Ceriello, A; Forst, T; Giorgino, F; Guerci, B; Heerspink, HJL; Itzhak, B; Ji, L; Kosiborod, M; Lalić, N; Lehrke, M; Marx, N; Nauck, M; Rodbard, HW; Rosano, GMC; Rossing, P; Rydén, L; Santilli, F; Schumm-Draeger, P-M; Vandvik, PO; Vilsbøll, T; Wanner, C; Wysham, C; Standl, E (2022) Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovasc Diabetol, 21 (1). p. 50. ISSN 1475-2840 https://doi.org/10.1186/s12933-022-01481-0
SGUL Authors: Rosano, Giuseppe Massimo Claudio

Preview

PDF Published Version
Available under License Creative Commons Attribution.
Download (900kB) | Preview

Official URL: https://doi.org/10.1186/s12933-022-01481-0

Abstract

The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18-19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year's focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1-5, and STEP 1-5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed.Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10-11, 2022 ( http://www.cvot.org ).

Item Type:

Article

Additional Information:

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Keywords: